Articles tagged with Prostate Cancer
Multispectral photoacoustic imaging distinguishes between benign and malignant prostate tissue with a high degree of accuracy. The new technique, which combines laser optics and ultrasound imaging technologies, predicts 25 out of 26 benign tissues and 13 out of 16 malignant tissues correctly.
A new study suggests that nearly half of all deaths from prostate cancer can be predicted before age 50, based on PSA levels. Focusing testing on men at highest risk may improve the benefits and harms of screening.
Researchers at Massachusetts General Hospital identified a genetic signature associated with the risk of tumor recurrence or spread in men surgically treated for prostate cancer. The 32-gene index proved to be the most accurate method, predicting actual incidence of tumor recurrence (47%) and metastasis (14%) among high-risk patients.
A new study reveals that correcting PSA levels for genetic variants can significantly reduce unnecessary biopsies and false complacency. By tailoring screening levels to an individual's genetic makeup, the risk of prostate cancer can be more accurately assessed. This approach has the potential to prevent up to 15% to 20% of biopsies.
Researchers identified BRCA2 gene mutation as first genetic factor for prostate cancer prognosis, associated with advanced disease and higher mortality rates. The study suggests a need for new treatment strategies for patients carrying these mutations.
The American College of Physicians (ACP) releases new recommendations for prostate cancer screening, focusing on shared decision-making and clear patient preference. Men between 50-69 years old should discuss the benefits and harms of PSA testing with their doctor before undergoing screening. The ACP also recommends against screening f...
Researchers at Virginia Tech have identified a genetically engineered Newcastle disease virus as a potential treatment for prostate cancer. The virus efficiently kills prostate cancer cells, including those resistant to hormone treatments and chemotherapy, while sparing normal human cells.
The American College of Physicians suggests that men between 50-69 discuss potential benefits and harms of the PSA test before screening. The risks include problems interpreting test results, biopsy complications, and treatment side effects. ACP recommends against testing in men younger than 50 or older than 69 with low life expectancy.
Researchers have developed a non-invasive test for metastatic prostate cancer using whole-genome analysis of plasma DNA, which identifies abnormal copy numbers of specific sequences. This breakthrough could aid personalized therapy and target treatment for castration-resistant prostate cancer.
A study published in the New England Journal of Medicine recommends continuous hormone therapy for metastatic prostate cancer, extending lives by months to years. Continuous therapy offers a better alternative to intermittent therapy with fewer side effects.
A new study of 1,535 patients with metastatic hormone-sensitive prostate cancer found that taking breaks from hormone-blocking treatments may not be as effective as continuous treatment. The study suggests that patients should be counseled about the potential risks of intermittent therapy if they wish to try it.
A CU Cancer Center study reveals that the transcription factor SPDEF regulates E-Cadherin production, inhibiting prostate cancer metastasis. The researchers found that increasing or decreasing SPDEF levels directly affects E-Cadherin expression, making it a crucial factor in preventing cancer spread.
Researchers found that SPOP mutations allow SRC-3 to proliferate and spread prostate cancer cells. The loss of SPOP's tumor-suppressing function enables SRC-3's cancer-promoting effects, making it an important target for prostate cancer treatment.
A new study links Lynch syndrome to a higher lifetime risk of prostate cancer and earlier age of onset, suggesting regular screening for men with the condition. The research estimates that men with Lynch syndrome have a 30% lifetime risk of developing prostate cancer, compared to 18% in the general population.
Researchers at Sanford-Burnham Medical Research Institute discovered that the enzyme PKCζ acts as a tumor suppressor in both mice and humans, controlling cell growth and metastasis. Restoring PKCζ levels may provide a novel therapeutic target for treating prostate cancer.
Scientists at the University of York have discovered a cancer-inducing DNA realignment in human prostate cancer stem cells that can lead to more effective therapies targeting the root cause of the disease. This breakthrough has challenged previous understanding of solid cancers and offers new opportunities for targeted treatments.
Genetic factors such as BRCA2 and HOXB13 play a crucial role in predicting high-risk prostate disease. Lifestyle factors including diet, exercise and geographic origin are also risk factors for PCa.
A study found that genetic testing can help identify BPH patients at higher risk of developing prostate cancer. Ten single nucleotide polymorphisms were linked to PCa risk, with one marker showing a strong association.
A study by Sanford-Burnham researchers found that Siah2 keeps androgen receptors constantly active in prostate cancer cells, enabling them to survive treatment. Inhibiting Siah2 may provide a new method for re-sensitizing castration-resistant prostate tumors to hormone therapy.
A joint Swedish-UK study found that men who participated in biennial PSA-based screening had lower risks of being diagnosed with and dying from prostate cancer for up to 9 years. After 9 years, the rates in both groups converged, but mortality was significantly lower in the screening group initially.
A Dutch study found that abiraterone can block androgen receptor activation directly, in addition to inhibiting CYP17A1 activity. This suggests a new mechanism of action for treating castration-resistant prostate cancer.
A large observational study conducted by a group of researchers in Sweden and the Netherlands suggests that surgery offers better survival benefits than radiotherapy for men with localized prostate cancer, especially in younger age groups and those with fewer comorbidities. The study found that radical treatment, preferably surgery, is...
Two novel radiolabeled small molecules targeting PSMA have excellent potential for diagnosing and staging prostate cancer. The imaging agents showed a high sensitivity of lesion detection in bone, soft tissue, and the prostate gland.
Researchers have developed a new focal laser ablation treatment that uses precisely targeted heat to burn away cancerous cells in the prostate. The approach has shown promising safety results and can be performed without significant side effects.
A UCLA study found that financial hardship, lack of doctor continuity and care coordination, and communication issues significantly hinder access to prostate cancer care among Latino men. The study highlights the need for a multi-faceted approach to improve access, increase health literacy, and enhance care coordination.
A study published in the Journal of Urology analyzed 25 years of data after radiation therapy for prostate cancer patients and found that follow-up evaluations are necessary for 15 years after treatment. The study also confirmed using radiation therapy results in comparable disease-free survival rates to radical prostatectomy.
A modified Newcastle disease virus has been developed to target prostate cancer cells without harming normal cells, offering a new treatment option for hormone-refractory patients. This oncolytic virus uses a retargeted design to minimize off-target losses and reduce the amount of virus needed for treatment.
A natural product called genistein-combined polysaccharide (GCP) may help patients with metastatic prostate cancer live longer by blocking a key mechanism used by prostate cancer cells to survive. GCP is expected to be effective in treating patients with low response to androgen-deprivation therapy.
A recent study found that radical prostatectomy (RP) lowers prostate cancer deaths in a subgroup of patients with a significant absolute mortality difference. However, another trial showed non-statistically significant results, raising questions about the impact of more frequent screening detection.
Research from the 2013 Genitourinary Cancers Symposium highlights new insights on high-risk prostate cancer prevalence and treatment. Studies show that African-American men and older men of any race are more likely to have aggressive prostate cancer, while surveillance for small kidney tumors is a safe alternative to surgery for elderl...
A recent study has found that exercise is linked with reduced prostate cancer risk in Caucasian men, but no such benefit is seen among African-American men. Furthermore, exercise also appears to lower the risk of high-grade prostate cancer in Caucasians compared to sedentary individuals.
Early-onset prostate cancer is linked to high levels of androgen receptor activity in young patients, leading to gene rearrangements that promote cancer. This discovery could lead to new diagnostic, prognostic, therapeutic, and prevention strategies for the disease.
A study published in JAMA Internal Medicine found that men's decisions to undergo prostate-specific antigen (PSA) screening are influenced by how information is presented. The researchers discovered that men who were given a balance sheet with relevant features of PSA screening were more likely to choose the screening option, while tho...
Early-onset prostate cancers have distinct genetic alterations that link genes normally independent to cancer-causing fusion genes. Androgen hormone receptors are also higher in younger patients, suggesting a potential trigger for the disease.
The Northwell Health system has received a federal grant to train Hampton University students on the racial disparities in prostate cancer treatments. The program aims to improve treatment outcomes for African American men, who are disproportionately affected by the disease.
A previously poorly investigated signalling pathway is crucial for prostate cancer cell proliferation, involving the production of cAMP at multiple locations in the cell. Inhibiting the soluble adenylyl cyclase enzyme suppresses cancer cell growth, suggesting a promising new therapeutic approach.
A recent study published in Annals of Internal Medicine suggests that exercising regularly earlier in life can significantly lower the risk of developing dementia later in life. Researchers analyzed data from over 19,000 adults and found a strong association between midlife fitness levels and reduced risk of all-cause dementia. Additio...
A new radiation therapy method using volume-modulated arc therapy (VMAT) has been shown to significantly reduce prostate cancer treatment time by approximately 14%. The study found that VMAT patients had shorter average room times, with some patients experiencing similar treatment times as those using gold-marker tracking.
A new study found differences in urinary, bowel, and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment. Men who underwent prostatectomy were more likely to experience urinary incontinence and erectile dysfunction.
A recent study by Fred Hutchinson Cancer Center found that regular consumption of deep-fried foods like French fries and doughnuts is associated with a higher risk of prostate cancer. The study suggests that frequent and regular consumption of these foods may be linked to more aggressive forms of the disease.
Researchers found that stress accelerates prostate cancer development in mice, while a genetic mutation in the NESP4 gene disrupts a cellular complex essential for hearing. Combining green tea extract with vardenafil enhances anti-cancer effects in a mouse model of multiple myeloma.
A recent study found that stress can accelerate prostate cancer development in mice, with adrenaline blocking cancer cell death. Conversely, drugs that inhibited adrenaline signaling ablated the effect of stress on prostate cancer. This suggests that beta-blockers could enhance the effectiveness of anti-cancer therapies.
A new study by Wake Forest Baptist researchers found that emotional stress can reduce the effectiveness of prostate cancer therapies and accelerate tumor growth. Stress-induced activation of a cell signaling pathway may lead to a vicious cycle of stress and cancer progression.
A new study finds that prostate cancer stigma is a significant barrier to diagnosis and treatment in Ghana, with many men diagnosed at late stages and opting out of therapy. The researchers aim to develop tailored treatment regimens and increase PSA screening rates to improve health outcomes.
Researchers discovered stable epigenetic marks across all metastatic tumors in each patient, defying the idea that these marks vary greatly within individuals. These consistent methylation changes appear to represent driver changes critical to cancer development and could be targets for treatment.
A two-year observational follow-up of the REDUCE trial found that dutasteride treatment was associated with a lower incidence of new prostate cancers. The study, published in The Journal of Urology, showed that men taking dutasteride had fewer prostate cancer diagnoses compared to those receiving a placebo.
A Kaiser Permanente study found that annual percent changes in prostate-specific antigen (PSA) levels are more accurate for detecting aggressive prostate cancer than single measurements. The study analyzed nearly 220,000 men and found a moderate increase in PSA levels with age.
A high-fiber diet, rich in inositol hexaphosphate (IP6), can control prostate cancer progression by inhibiting tumor growth and slowing glucose metabolism. Researchers found that IP6 reduced tumor volumes and slowed glucose metabolism in prostate cancer models.
A comprehensive study analyzed 232 papers on prostate cancer treatments and found that surgery is the most cost-effective option, saving lives at a lower cost than radiation therapy. The analysis also showed that treatment plans for localized prostate cancer vary dramatically across different centers.
A study by Dana-Farber Cancer Institute found that a small percentage of men treated for prostate cancer reported a perceived shortening of their penis, leading to regrets about treatment choice. The complaint was more common in men treated with radical prostatectomy or male hormone-blocking drugs combined with radiation therapy.
Thomas Jefferson University researchers have identified new pathways that drive aggressive forms of prostate cancer. Elevated levels of Cyclin D1b function as a novel biomarker for lethal metastatic disease in prostate cancer patients.
A preclinical study found that androgen deprivation therapies may have adverse effects on prostate cancer growth and survival in men with precancerous conditions. The study's results suggest that reducing testosterone levels may encourage indolent tumors to become more aggressive as men age.
Researchers at the Kimmel Cancer Center at Jefferson developed diagnostic and prognostic genetic tests to better predict prostate cancer survival outcomes. The tests distinguish clinically-relevant cancers from normal prostate tissue in men with elevated PSA levels, offering a superior alternative to existing gene tests and the Gleason...
Researchers at Mayo Clinic have identified an enzyme specifically linked to aggressive prostate cancer, which promotes the metastatic spread of the disease. A compound that inhibits this enzyme's ability has been developed and shows promise for future clinical applications.
A study published in the Journal of the National Cancer Institute found no significant difference in toxicity between proton radiotherapy (PRT) and intensity-modulated radiotherapy (IMRT) among Medicare beneficiaries with prostate cancer at 12 months post-treatment. Despite its widespread use, PRT's benefits and harms remain unknown.
A new Australian study finds that large regions of the genome are epigenetically activated in prostate cancer, including genes like PSA and PCA3. The study also identifies 'epigenetic master controllers' that can switch on or off large regions of DNA, with significant implications for cancer diagnosis and treatment.
Dana-Farber Cancer Institute scientists identify EZH2 as a key player in prostate cancers that no longer respond to hormone-blocking treatments. The researchers suggest that drugs targeting EZH2's unexpected function could be an effective new treatment strategy for these aggressive cancers.
A new targeted prostate biopsy technique using magnetic resonance ultrasound fusion has been shown to improve diagnosis of prostate cancer and aid in selecting patients for active surveillance. The study found that the biopsies identified 90 out of 171 men with prostate cancer, highlighting its potential as a more accurate and efficien...
A new imaging-guided targeted biopsy method using MRI and ultrasound fusion has been shown to detect prostate cancer more accurately than traditional blind biopsies. The technique led to a high rate of cancer detection and identification of aggressive tumors, improving patient outcomes.
The growing US population and increased life expectancy necessitate new approaches to prostate cancer treatment. Researchers are exploring targeted therapies, immunotherapy, and precision radiation targeting to improve treatment outcomes for older patients.